There is no published trial data on psilocybin for PTSD

Absence of evidence is not evidence of absence

This needs saying explicitly, because pages like this one are easy to misread in the opposite direction. Nothing here shows that psilocybin fails in PTSD. No trial has found it ineffective, because no trial has been published either way.

There are reasons to think the question is worth asking. Psilocybin has produced real results in alcohol use disorder in the best-designed trial in the field^[2] and statistically significant if modest results in depression. PTSD frequently co-occurs with both. A researcher who wanted to run this trial would not be being unreasonable.

But a reason to run a trial is not a result from one. The claim we are making is narrow and we will hold to it: nobody currently knows, and anyone charging money on the basis that they do is charging for something unevidenced.

Psilocybin is not MDMA, and the difference is the entire evidence base

Readers conflate these constantly, and the marketing does nothing to discourage it. They are different compounds. They act differently, feel different, and — the part that matters here — have entirely different research records in PTSD.

MDMA-assisted therapy has been studied in PTSD and is what most people are thinking of when they picture “psychedelic therapy for trauma”. Psilocybin has not been studied in published PTSD trials. The VA’s own assessment covers both compounds, and places neither in the VA/DoD Clinical Practice Guideline for PTSD.^[1] We are not going to characterize the size or the quality of the MDMA literature here, because that is a different page and we would be summarizing trials we have not put through our own ledger.

The practical consequence is simple. Reading about MDMA trial results and then buying psilocybin is a substitution nobody has tested.

Why veterans are the target, and why that matters more than usual

Psilocybin marketing for PTSD is aimed at veterans with an intensity it is not aimed at anyone else. The reasons are structural rather than sinister, which is precisely why the pattern is stable.

• PTSD is common in this population. The VA operates a National Center for PTSD and publishes clinical guidance on it; the demand is real and concentrated.
• Established treatment does not work for everyone. The VA/DoD guideline recommends treatments that have been tested in trials. Trials report averages, and people for whom the recommended options have failed are left looking for what is next.
• The cost falls on the individual. Psilocybin services in the legal state programs are not covered by insurance and are paid for out of pocket. A veteran spending several thousand dollars on an unevidenced treatment for PTSD is exposed twice — financially, and to the disappointment of another thing that did not work.

The VA has published its position on psychedelic-assisted therapy for PTSD, which tells you how much interest there is. What that document says is that the data are not there.^[1] That is a federal health system with every incentive to find something that works for its own patients, reporting that this has not been shown to.

What treatment actually costs, and who pays, is set out on our cost page. Where any of this is legal at all is on the state-by-state tracker.

What would change this page

Published controlled data of any quality. We are setting the bar deliberately low, because the current state is zero and almost anything would be an improvement on it. A small randomized trial, even an imperfect one, would move PTSD out of the empty column and into the ledger — reported with its sample size, its comparator, its blinding and its limitations, like everything else here.

Until then this page will keep saying the same thing, and we will keep saying it in the same words. A press release is not a trial. A registered study is not a result. An anecdote at scale is still an anecdote.